Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EBIT: 2019-2024

Historic EBIT for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$415.6 million.

  • Beam Therapeutics' EBIT fell 19.07% to -$126.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$466.3 million, marking a year-over-year decrease of 155.26%. This contributed to the annual value of -$415.6 million for FY2024, which is 135.47% down from last year.
  • As of FY2024, Beam Therapeutics' EBIT stood at -$415.6 million, which was down 135.47% from -$176.5 million recorded in FY2023.
  • Beam Therapeutics' EBIT's 5-year high stood at -$132.8 million during FY2020, with a 5-year trough of -$415.6 million in FY2024.
  • Moreover, its 3-year median value for EBIT was -$338.5 million (2022), whereas its average is -$310.2 million.
  • As far as peak fluctuations go, Beam Therapeutics' EBIT tumbled by 195.62% in 2021, and later soared by 47.86% in 2023.
  • Beam Therapeutics' EBIT (Yearly) stood at -$132.8 million in 2020, then slumped by 195.62% to -$392.5 million in 2021, then rose by 13.76% to -$338.5 million in 2022, then soared by 47.86% to -$176.5 million in 2023, then slumped by 135.47% to -$415.6 million in 2024.